Market Overview

UPDATE: Feltl and Company Raises PT to $121 on DaVita Post Solid Q3

Related DVA
UPDATE: KeyBanc Capital Markets Downgrades DaVita HealthCare Partners Inc On Balanced Risk/Reward
Benzinga's Top Downgrades

Feltl and Company reiterated its Buy rating on DaVita (NYSE: DVA) and raised its price target from $111 to $121.

Feltl and Company said, "Solid revenue metrics effectively inline with our expectations: Gross revenue increased 12% over prior year to $2,023 million. Non-acquired revenue increased 4.4%; we believe anything between 4%-5% growth is more than respectable given the mature dynamics of the industry. DVA acquired 10 centers and opened 21 centers in the U.S. and 2 centers outside the U.S. Through three quarters DVA has acquired 71 centers and opened 48 in the U.S. While acquiring facilities can ebb and flow we maintain smaller dialysis operators simply are finding the bundle reimbursement environment more challenging, and we expect continued acquisition activity over the next one to two years."

DaVita closed at $111.02 on Friday.

Latest Ratings for DVA

DateFirmActionFromTo
Sep 2014KeyBancDowngradesBuyHold
Aug 2014Deutsche BankDowngradesBuyHold
Jul 2014Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: Feltl And CompanyAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (DVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters